Alliances
The two companies will invest as partners in global medtech enterprises with the goal of accelerating their market entry and commercialization in China.
Will this new buy be enough for Celgene investors?
Gene therapy treatment is a high risk, high reward venture, but the promises of a therapy developed through these programs could be life-changing for patients.
The latest collaborations bring the total number of strategic transactions executed by J&J Innovation to more than 350 since its establishment in 2012.
Takeda CEO Christophe Weber is sticking to his game plan of actively hunting deals that will expand its global presence and create a stronger international profile.
Pfizer will use Arvinas’ proprietary PROTAC Platform to create small molecule therapeutics aimed at degrading disease-causing cellular proteins.
Sangamo and Pfizer will use the company’s ZFP-TFs to develop the treatments that are linked to mutations of the C9ORF72 gene, which can cause both ALS and FTLD.
The deal was originally inked on Jan 17, 2014.
The incubator will be located at Merck Serono’s current facilities in Yavne, a town in central Israel.
Nanjing Legend Biotech received a very large $350M upfront payment from Janssen Biotech to partner Legend’s impressively effective CAR-T candidate.
PRESS RELEASES